Nanobiotix shares among the leaders of the SBF 120, but down 12.9% over the week
The Parisian oncology nanomedicine biotech rebounds sharply at midday, in a Paris market slightly higher. This recovery follows a week of marked decline, right after two meetings between management and the financial community in London.
A rebound that recovers only part of the weekly decline
Nanobiotix shares gain 5.15% to €25.32, placing them second in the SBF 120, behind Soitec, while the index advances 0.34%. The stock nevertheless remains below its three moving averages: the MM20 is at €27.45, a gap of 7.76% with the price, and the MM200 at €29.88.
Over one week, the stock still falls 12.93%, so the gain of the day mitigates this decline without erasing it. Over one month, by contrast, it retains a gain of 32.43%, earned during the sharp recovery in the first half of November.
A listing on two markets and cash announced through 2029
Nanobiotix is a single company listed on two markets: the ordinary share on Euronext Paris and the ADS on Nasdaq, at a ratio of one ADS for one share. The two lines mainly move on the same day, and only the Parisian line is eligible for the PEA.
On the fundamentals, first-half 2026 results, published on September 24, reported cash of €110.9 million, described as sufficient to finance operations through 2029.
The group is developing the radioamplifier NBTXR3 (JNJ-1900) with Johnson & Johnson. The latest clinical data date back to the ESMO congress of October 24, with a median overall survival of 17.8 months in anti-PD-1-resistant melanoma. The stock now trades between its support at €18.85 and its resistance at €30.36.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.